BR112016016021B1 - Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única - Google Patents

Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única Download PDF

Info

Publication number
BR112016016021B1
BR112016016021B1 BR112016016021-5A BR112016016021A BR112016016021B1 BR 112016016021 B1 BR112016016021 B1 BR 112016016021B1 BR 112016016021 A BR112016016021 A BR 112016016021A BR 112016016021 B1 BR112016016021 B1 BR 112016016021B1
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
composition
acceptable salt
weight
pharmaceutical composition
Prior art date
Application number
BR112016016021-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016016021A8 (pt
BR112016016021A2 (pt
Inventor
Mahesh Padval
Paul Okwabi Nkansah
Original Assignee
Verastem, Inc.
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem, Inc., Pfizer Inc filed Critical Verastem, Inc.
Publication of BR112016016021A2 publication Critical patent/BR112016016021A2/pt
Publication of BR112016016021A8 publication Critical patent/BR112016016021A8/pt
Publication of BR112016016021B1 publication Critical patent/BR112016016021B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
BR112016016021-5A 2014-01-09 2015-01-09 Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única BR112016016021B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
US61/925,467 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Publications (3)

Publication Number Publication Date
BR112016016021A2 BR112016016021A2 (pt) 2017-09-19
BR112016016021A8 BR112016016021A8 (pt) 2018-04-17
BR112016016021B1 true BR112016016021B1 (pt) 2023-01-10

Family

ID=52434976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016016021-5A BR112016016021B1 (pt) 2014-01-09 2015-01-09 Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única

Country Status (15)

Country Link
US (3) US20150190346A1 (https=)
EP (2) EP3091981B1 (https=)
JP (5) JP6647204B2 (https=)
KR (3) KR102444494B1 (https=)
CN (3) CN119868364A (https=)
AU (4) AU2015204597B2 (https=)
BR (1) BR112016016021B1 (https=)
CA (1) CA2936283C (https=)
DK (1) DK3091981T3 (https=)
ES (1) ES2870562T3 (https=)
IL (2) IL246667B (https=)
MX (2) MX384259B (https=)
NZ (2) NZ721934A (https=)
SG (2) SG10201805890QA (https=)
WO (1) WO2015106096A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
EP4125896B1 (en) * 2020-03-27 2025-05-07 Pfizer Inc. Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
SI3965742T1 (sl) * 2020-04-24 2023-10-30 Dr. Falk Pharma Gmbh Sistemska formulacija piridinonskega derivata za bolezni, povezane s tg2
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP1653926A1 (en) * 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
MX2011001782A (es) * 2008-08-13 2012-02-08 Vertex Pharma Composicion farmaceutica y su administracion.
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2012027247A2 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
EP2654726A1 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法

Also Published As

Publication number Publication date
CN106102744A (zh) 2016-11-09
AU2020210153A1 (en) 2020-08-13
MX2016009056A (es) 2017-01-23
JP2017502062A (ja) 2017-01-19
CN115708827A (zh) 2023-02-24
AU2015204597B2 (en) 2020-04-30
JP2022001587A (ja) 2022-01-06
IL292054A (en) 2022-06-01
WO2015106096A1 (en) 2015-07-16
BR112016016021A8 (pt) 2018-04-17
NZ721934A (en) 2022-04-29
AU2020210153B2 (en) 2022-07-21
DK3091981T3 (da) 2021-05-31
ES2870562T3 (es) 2021-10-27
KR20240159639A (ko) 2024-11-05
IL246667A0 (en) 2016-08-31
AU2015204597A1 (en) 2016-07-21
MX384259B (es) 2025-03-14
KR20220130251A (ko) 2022-09-26
EP3091981A1 (en) 2016-11-16
AU2025204843A1 (en) 2025-07-17
US20150190346A1 (en) 2015-07-09
EP3900726A1 (en) 2021-10-27
SG10201805890QA (en) 2018-08-30
CA2936283C (en) 2023-02-28
CN119868364A (zh) 2025-04-25
AU2022256144A1 (en) 2022-11-24
JP2020007355A (ja) 2020-01-16
US20230104303A1 (en) 2023-04-06
EP3091981B1 (en) 2021-03-10
AU2022256144B2 (en) 2025-04-03
JP6647204B2 (ja) 2020-02-14
IL246667B (en) 2022-05-01
KR20160104725A (ko) 2016-09-05
US20200038331A1 (en) 2020-02-06
BR112016016021A2 (pt) 2017-09-19
MX2021008225A (es) 2021-08-11
KR102444494B1 (ko) 2022-09-20
JP2023065568A (ja) 2023-05-12
NZ760233A (en) 2022-04-29
JP2025084892A (ja) 2025-06-03
SG11201605588YA (en) 2016-08-30
CA2936283A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
AU2022256144B2 (en) Compositions and methods for treatment of abnormal cell growth
JP2021501142A (ja) キナーゼを調節する化合物の製剤
US8741344B1 (en) Dispersible tablet
ES3048983T3 (en) A plurality of tasquinimod particles and use thereof
HK40062771A (en) Compositions and methods for treatment of abnormal cell growth
HK1230956B (en) Compositions and methods for treatment of abnormal cell growth
WO2014075692A1 (en) Dispersible tablet
HK1230942A1 (en) Compositions and methods for treatment of abnormal cell growth
JP7287955B2 (ja) シス－４－［２－｛［（３ｓ，４ｒ）－３－フルオロオキサン－４－イル］アミノ｝－８－（２，４，６－トリクロロアニリノ）－９ｈ－プリン－９－イル］－１－メチルシクロヘキサン－１－カルボキサミドの組成物及び使用方法
KR20260022394A (ko) 에스트로겐 수용체 분해제의 고형 경구제
RU2586290C1 (ru) Твердая лекарственная форма прокарбазина немедленного высвобождения и способ ее получения
CN119365195A (zh) 含有匹米替比的医药组合物
BR122024022942A2 (pt) Composições farmaceuticamente aceitáveis para administração oral, comprimidos farmaceuticamente aceitáveis, usos relacionados, processo para a preparação de uma dispersão sólida, dispersão sólida e kit compreendendo a composição
JP2023502264A (ja) 固体用量医薬組成物

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/01/2015, OBSERVADAS AS CONDICOES LEGAIS